FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHA
Instruction 1(b).	Filed pursuant to Section

## NGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  REINHARDT MAX					2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [ PCRX ]									heck all app Direc	ationship of Reportir k all applicable) Director Officer (give title		10% Ov	ner
		CIENCES, INC.			ate of E		Transa	action (N	lonth/	/Day/Year)				belov	v) resident, F	Rest o	below) of World	
890	EST KENN.	EDY BOULEVA	ARD, SUITE	4. lf .	Amend	Iment,	Date of	f Origina	l Filed	d (Month/Da	y/Yea	r)	6. Lin	Individual or	Joint/Grou	ıp Filin	ıg (Check A	pplicable
(Street)														- /	filed by On	e Rep	orting Pers	on
TAMPA	FL	3	3609	_										Form Perso		re tha	n One Repo	orting
(City)	(Sta	ate) (Z	Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				ay/Year) Exec		a. Deemed secution Date, any lonth/Day/Year)		Transaction Disposed Code (Instr. 5)		ies Acquired (A Of (D) (Instr. 3,			nd Securit Benefic	ies cially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									v	Amount	(A (D	(A) or (D)		Transa	ed ction(s) 3 and 4)			(Instr. 4)
Common Stock 10/07/			7/2022	2022		<b>S</b> <sup>(1)</sup>		1,380		D	\$58	31,378 <sup>(2)</sup>			D			
		Tal	ole II - Deriva (e.g., p							osed of, onvertib					d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion or Exercise (Month/Day/Year)   Execution Date, if any (Month/Day/Year)   Execution Date, if any (Month/Day/Year)   Security   Execution Date, if any (Month/Day/Year)   Execution Date, if		vative irities ired r osed )	Expiration Date (Month/Day/Year) Amount Securitie Underlyi Derivativ Security 3 and 4)				unt of irities erlying vative irity (li d 4)	nstr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	or Nun of	ount nber res					

## **Explanation of Responses:**

- 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- 2. Includes 408 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022.

## Remarks:

/s/ Kristen Williams, Attorney-in-Fact

10/11/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.